-
Uncategorized4 weeks ago
Editor’s pick: Dispatch Biotherapeutics
Nature Biotechnology, Published online: 18 August 2026; doi:10.1038/s41587-026-03293-z Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Dispatch Bio delivers...
-
Uncategorized4 weeks ago
Albumin-Fused Antibodies May Reduce Fetal Exposure to Therapeutics
Researchers at the University of Oslo and Oslo University Hospital, together with national and international collaborators, have reported on the results of preclinical research that could...
-
Uncategorized4 weeks agoMalaria Mosquito Bites Turned Into Immune Boosters in New Chemovaccination Strategy
More than 600,000 people—predominantly pregnant women and children under the age of five—die from malaria every year. According to the World Health Organization, one child in...
-
Uncategorized4 weeks agoSTAT+: Sanofi to lay off 229 workers in Mass., a year after $9.1B Blueprint Medicines acquisition
Sanofi, one of Massachusetts’ largest pharmaceutical employers, will lay off 229 workers, according to records the company filed with the state. The workers losing their jobs...
-
Uncategorized4 weeks agoSTAT+: Eyepoint study results for vision treatment disappoint, but company still sees promise
Eyepoint said Monday that patients administered its experimental treatment for a common cause of age-related blindness failed to maintain vision with less frequent injections compared to...
-
Uncategorized4 weeks ago
University of Rhode Island Wins Grant to Study Cerebral Amyloid Angiopathy Prevalent in Alzheimer’s Patients
A professor of pharmaceutical and biomedical sciences at the University of Rhode Island’s (URI) College of Pharmacy received a $1.5 million grant to research cerebral amyloid angiopathy...
-
Uncategorized4 weeks agoThe Microbiome Field Enters Its Next Chapter
Sebastião van Uden, PhDCEO, Bac3Gel When scientists at Bac3Gel hear from potential customers, they typically express a mixture of frustration, curiosity, and skepticism, Sebastião van Uden,...
-
Uncategorized4 weeks agoPharma Races to Scale AI as Billions Flow into Drug Discovery
The infrastructure moment for AI-driven drug discovery continues to accelerate, with billion-dollar investments flowing into end-to-end platforms driven by models and compute, rather than single drug...
-
Uncategorized4 weeks agoArgenx jumps on Phase 3 data for blockbuster Vyvgart
The latest results give investors confidence in the drug’s ability to be approved in another indication for which there are no approved treatments.
-
Uncategorized4 weeks agoEyePoint plummets on pivotal data for main drug
Though its drug missed the main goal of a wet AMD study, EyePoint, as well as analysts, still see a path toward approval. Investors may be...
FDA clears first generic radioligand drug; Sionna turns to layoffs
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
Ensuring safety and accountability in China’s biomedical translation system
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
